Celgene Corp. Given New $175.00 Price Target at RBC Capital (CELG)
RBC Capital lifted their price objective on shares of Celgene Corp. (NASDAQ:CELG) from $170.00 to $175.00 in a research note issued on Friday, Stock Ratings Network reports. The firm currently has an “outperform” rating on the stock. RBC Capital’s target price would suggest a potential upside of 12.37% from the company’s current price.
Celgene Corp. (NASDAQ:CELG) traded down 1.41% on Friday, hitting $155.74. 3,234,185 shares of the company’s stock traded hands. Celgene Corp. has a 1-year low of $70.42 and a 1-year high of $151.00. The stock’s 50-day moving average is $142.3 and its 200-day moving average is $125.4. The company has a market cap of $64.052 billion and a P/E ratio of 44.17.
Celgene Corp. (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, October 24th. The company reported $1.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.02. The company had revenue of $1.67 billion for the quarter, compared to the consensus estimate of $1.64 billion. During the same quarter in the previous year, the company posted $1.29 earnings per share. The company’s revenue for the quarter was up 18.0% on a year-over-year basis. On average, analysts predict that Celgene Corp. will post $5.98 earnings per share for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at JMP Securities raised their price target on shares of Celgene Corp. from $160.00 to $175.00 in a research note to investors on Friday. Separately, analysts at Credit Suisse raised their price target on shares of Celgene Corp. from $135.00 to $165.00 in a research note to investors on Friday. They now have a “neutral” rating on the stock. Finally, analysts at BMO Capital Markets raised their price target on shares of Celgene Corp. from $180.00 to $200.00 in a research note to investors on Friday. They now have an “outperform” rating on the stock. Five equities research analysts have rated the stock with a hold rating and twenty-one have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $153.78.
Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.